Magnetic Heart Pump Helps Heart Failure Patients
By HospiMedica International staff writers Posted on 31 Oct 2018 |
Image: The MagLev HeartMate 3 LVAD system (Photo courtesy of Abbott).
An innovative left ventricular assist device (LVAD) can help advanced heart failure (HF) patients who are not eligible for heart transplants enjoy a better quality of life for the rest of their days.
The Abbott (Abbott Park, IL, USA) HeartMate 3 consists of a magnetically levitated (MagLev) centrifugal-flow pump implanted above the diaphragm, next to the native heart; the pump is attached to the aorta, thus leaving natural circulation in place. The system can pump up to 10 liters of blood per minute, using magnets keep the rotor in place, reducing trauma to blood cells passing through the pump while improving flow. The pump also adds consistently timed flow gaps in order to generate an artificial pulse which further reduces adverse events, including combating the formation of thrombii.
The MagLev system is calibrated tens of thousands of times per second to ensure it stays suspended and centered within the pump, no matter the speed settings used by a physician, ensuring that the pump is performing effectively. The patient himself wears an external, wearable controller, the system driveline, and a battery that powers the pump. Recent clinical data shows that patients implanted with the Abbot HeartMate 3 LVAD enjoyed a survival rate of 82.8% at two years follow-up, and that rates of suspected pump thrombosis were just 1.1% at two years.
“We partner with physicians to holistically develop therapies that benefit patients and achieve better outcomes,” said Mike Pederson, senior vice president of Abbott's Cardiac Arrhythmias and HF business. “The unique design of the HeartMate 3 LVAD, with its full MagLev technology, takes an established innovation and improves upon it in meaningful ways to help people with advanced heart failure live fuller lives.”
“Approximately a quarter of a million people are living with advanced heart failure, and many of these people will need a heart transplant; however, only a few thousand will receive a new heart,” said Nir Uriel, MD, of the University of Chicago Medicine (IL, USA). “Destination therapy approval for Abbott's HeartMate 3 device now gives these patients new hope that they can receive a heart pump clinically proven to mitigate challenges we've historically confronted with this therapy—stroke and blood clotting—while also offering survival rates on par with transplant.”
An LVAD is intended to complement a weakened heart by providing circulatory support, thus helping to maintain or improve blood flow to the kidneys, liver, brain and other organs. One end is attached to the left ventricle, and other is attached to the aorta; blood flows from the ventricles into the pump and is then ejected out of the device and into the aorta. LVADs are used as destination therapy or as a bridge-to-transplant, allowing the patient to be discharged from the hospital and lead a more normal and fuller life.
The Abbott (Abbott Park, IL, USA) HeartMate 3 consists of a magnetically levitated (MagLev) centrifugal-flow pump implanted above the diaphragm, next to the native heart; the pump is attached to the aorta, thus leaving natural circulation in place. The system can pump up to 10 liters of blood per minute, using magnets keep the rotor in place, reducing trauma to blood cells passing through the pump while improving flow. The pump also adds consistently timed flow gaps in order to generate an artificial pulse which further reduces adverse events, including combating the formation of thrombii.
The MagLev system is calibrated tens of thousands of times per second to ensure it stays suspended and centered within the pump, no matter the speed settings used by a physician, ensuring that the pump is performing effectively. The patient himself wears an external, wearable controller, the system driveline, and a battery that powers the pump. Recent clinical data shows that patients implanted with the Abbot HeartMate 3 LVAD enjoyed a survival rate of 82.8% at two years follow-up, and that rates of suspected pump thrombosis were just 1.1% at two years.
“We partner with physicians to holistically develop therapies that benefit patients and achieve better outcomes,” said Mike Pederson, senior vice president of Abbott's Cardiac Arrhythmias and HF business. “The unique design of the HeartMate 3 LVAD, with its full MagLev technology, takes an established innovation and improves upon it in meaningful ways to help people with advanced heart failure live fuller lives.”
“Approximately a quarter of a million people are living with advanced heart failure, and many of these people will need a heart transplant; however, only a few thousand will receive a new heart,” said Nir Uriel, MD, of the University of Chicago Medicine (IL, USA). “Destination therapy approval for Abbott's HeartMate 3 device now gives these patients new hope that they can receive a heart pump clinically proven to mitigate challenges we've historically confronted with this therapy—stroke and blood clotting—while also offering survival rates on par with transplant.”
An LVAD is intended to complement a weakened heart by providing circulatory support, thus helping to maintain or improve blood flow to the kidneys, liver, brain and other organs. One end is attached to the left ventricle, and other is attached to the aorta; blood flows from the ventricles into the pump and is then ejected out of the device and into the aorta. LVADs are used as destination therapy or as a bridge-to-transplant, allowing the patient to be discharged from the hospital and lead a more normal and fuller life.
Latest Surgical Techniques News
- Miniaturized Ultrasonic Scalpel Enables Faster and Safer Robotic-Assisted Surgery
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery
- Robotic Nerve ‘Cuffs’ Could Treat Various Neurological Conditions
- Flexible Microdisplay Visualizes Brain Activity in Real-Time To Guide Neurosurgeons